CSOP HS Biotech(03174.HK) +2.81%, Hengrui 9M net profit up 20.38%

NewTimeSpace News: As of 11:38 HKT on October 28, 2026, CSOP HS Biotech(03174.HK) rose 2.81% intraday to HK$3.436 on turnover of HK$827,300 and a turnover rate of 0.10%.

NewTimeSpace understands that CSOP HS Biotech(03174.HK), managed by CSOP Asset Management Limited, tracks the Hang Seng Biotech Index, which covers biotech and related pharmaceutical companies listed in Hong Kong. As of 11:38 HKT on October 28, the ETF had assets of HK$862 million, a net asset value of HK$3.357 per unit and a board lot of 100 shares.

On the news front, Hengrui Pharma disclosed on the evening of October 27 that its revenue for the first nine months of 2026 was CNY24.409 billion, up 5.26% year on year, with net profit attributable to shareholders of CNY6.923 billion, up 20.38%; third-quarter net profit rose 88.92% year on year, with both revenue and profit recovering from the second quarter. Separately, Securities Times reported that 29 Chinese innovative drug studies were selected as late-breaking abstracts at the 2026 ESMO Congress held from October 23 to 27, about one third of the total and a record high.

Kaiyuan Securities said in a research note that Chinese developers rapidly taking on a role of differentiated innovation and global development in oncology R&D.